|
|
|
| The Monthly Pulse |
|
|
| History made: Young child treated with new heart device for very first time
|
|
| The Story |
|
| An Illinois-based care team recently performed the first heart procedure of its kind on a two-year-old with Brugada syndrome. The patient experienced a sudden cardiac arrest and received CPR from his parents, then EMS, before being transported to the ICU. During the minimally invasive procedure, doctors successfully implanted an extravascular implantable cardioverter-defibrillator (EC-ICD). |
| |
| What You Should Know |
|
| While EC-ICD devices are typically only implanted in older patients, doctors were confident that this option would provide the best chances for a long and healthy life in the young patient. Historically, children would have to go through more invasive procedures or receive larger devices, but the advent of new technology is facilitating less-invasive options. The EC-ICD by Medtronic is the first commercially available ICD in the U.S. placed outside the vascular space.
|
| |
|
|
| |
|
| ‘A victory for TAVR’: How treatment impacts elderly patients in their last year of life
|
|
| The Story |
|
| According to recent data, elderly patients who have undergone transcatheter aortic valve replacement (TAVR) may have an increased risk of hospitalization during their last year of life. Yet, researchers who uncovered these findings note that neither TAVR itself nor any issues related to it are to blame; rather, general frailty and various comorbidities appear to be the culprits.
|
| |
| What You Should Know |
|
| Researchers note that most of the hospitalizations that occurred among the subjects studied were not due to cardiovascular causes. While the need for medical care and likelihood for hospitalization are greater for patients who have undergone TAVR, differences from elderly individuals who have not received TAVR are not overwhelming. Researchers believe that TAVR restores patients to a status comparable to the general elderly population, and therefore consider these findings a win in favor of TAVR.
|
| |
|
|
| |
|
| Aspirin and Hemocompatibility After LVAD Implantation in Patients With Atherosclerotic Vascular Disease: A Secondary Analysis From the ARIES-HM3 Randomized Clinical Trial |
|
| The Story |
|
| For many years, aspirin has been recommended for secondary prevention in several chronic cardiovascular conditions, including peripheral vascular disease, cerebral vascular disease, and others. In patients with heart failure, these comorbidities are common, and roughly half take aspirin regularly. In advanced heart failure, left ventricular assist devices (LVADs) are often used to enhance survival and quality of life. To prevent thrombotic complications, antithrombotic regimens are required. Thus, researchers recently sought to determine whether common conditions for which aspirin is indicated influence outcomes when aspirin is eliminated in recipients of the Heartmate 3 LVAD. |
| |
| What You Should Know |
|
| According to a secondary analysis of the Aspirin and Hemocompatibility Events with a Left Ventricular Assist Device in Advanced Heart Failure (ARIES-HM3) randomized clinical trial, having an atherosclerotic vascular condition did not modify the observed benefit of aspirin avoidance on the primary outcome of survival. In other words, prior stroke, percutaneous coronary intervention (PCI), peripheral vascular disease, and coronary artery bypass grafting should not compel physicians to use aspirin as part of an antithrombotic regimen with the HM3 LVAD.
|
| |
|
|
| |
|
| 2025 AANP Health Policy Conference |
| Sun., Mar. 2 - Tues., Mar. 4 |
|
|
| |
|
AAPA Executive Leadership Conference |
| Mon., Mar. 3 - Wed., Mar. 5 |
|
|
| |
| Houston Aortic Symposium |
| Thurs., Mar. 6 - Sat., Mar. 8 |
|
|
| |
| AmSECT International |
| Wed., Mar. 19 - Sun., Mar. 23 |
|
|
| |
| AORN Global Surgical Conference & Expo |
| Sat., Apr. 5 - Tues., Apr. 8 |
|
|
| |
|
|
|
